Clinical Trial Update: Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating FE 202158 as a primary treatment in patients with early septic shock has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Septic Shock

Drugs mentioned

• FE 202158

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Septic Shock | Phase 2 | Status: COMPLETED | Results posted: 2017-01-16